Pfizer Lipitor Patent Found Invalid By Patent & Trademark Office
This article was originally published in The Pink Sheet Daily
Executive Summary
PTO rejects claims in patent ’156, covering crystalline form of atorvastatin, after finding product is covered in two earlier patents. Pfizer says decision is “preliminary” and plans to respond “in due course.”